Clinical trials
Metastatic Malignant Neoplasm clinical trials
Below are recruiting metastatic malignant neoplasm clinical trials, each written for real people, not researchers. We’re tracking 247 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07162675Recruiting
Step count and treatment response in breast cancer patients
This study looks at how your daily step count, measured by a smartwatch, relates to how well your breast cancer responds to treatment before surgery. It may help show if being more active during chemotherapy leads to better outcomes.
Ankara, YenimahalleAges 18 years+ - NCT07030712RecruitingPhase 1
Study of MK-8294 for advanced solid tumors
This trial tests an experimental drug called MK-8294 for people with advanced solid tumors that have stopped responding to standard treatments. It may be an option if you have certain types of cancer and are looking for a new treatment.
Chicago, IllinoisAges 18 years+ - NCT06208371RecruitingPhase 3
Local treatment vs. chemo for colorectal cancer with many liver spots
This trial tests whether treating all liver tumors with surgery, ablation, or radiation is better than continuing standard chemotherapy for people with colorectal cancer that has spread only to the liver. It's for those whose liver tumors have been controlled by initial chemotherapy and are considered removable.
Guangzhou, GuangdongAges 18 years+ - NCT06979596RecruitingPhase 2
A study of MK-5684 for certain solid tumors
This trial tests an investigational drug called MK-5684 for people with specific types of breast, ovarian, or endometrial cancer. It aims to see if this treatment can help shrink or control the cancer when standard treatments have stopped working or are no longer effective.
Anchorage, AlaskaAges 18 years+ - NCT06941272RecruitingPhase 1/Phase 2
Study of patritumab deruxtecan for children with hard-to-treat solid tumors
This trial tests a new drug, patritumab deruxtecan, in children and adolescents whose rhabdomyosarcoma or hepatoblastoma has returned or not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
Los Angeles, CaliforniaAges 1 month–17 years - NCT06818643RecruitingPhase 1/Phase 2
Study of MK-3120 for advanced solid tumors
This trial tests an investigational drug called MK-3120 for people with advanced solid tumors (cancer that has spread or cannot be removed). It is for patients whose cancer has progressed after standard treatments, and it aims to see if the drug is safe and effective.
Birmingham, AlabamaAges 18 years+ - NCT06782451Recruiting
Testing tumor samples to find new treatments based on DNA changes
This trial takes a sample of your tumor during a standard procedure to grow it in a lab and test different drugs. The goal is to find which drugs might work best for people with your specific tumor DNA change.
NiceAges 18 years+ - NCT06778382RecruitingPhase 2
Delaying treatment after destroying lung spots from colorectal cancer
This trial tests if it's safe to wait before starting full-body therapy after treating a small number of lung tumors (5 or fewer) in people whose colorectal cancer had been gone for at least 6 months. You would first get local treatments like surgery or radiation to destroy the lung spots, then delay additional cancer drugs to see how you do.
Jinan, ShandongAges 18–75 - NCT06574880RecruitingPhase 1/Phase 2
Radiation and Lutetium PSMA for locally advanced prostate cancer
This study tests a combination of focused radiation (SBRT) and a targeted radioactive drug (Lutetium PSMA) for men with prostate cancer that has spread to nearby lymph nodes or has high-risk features but has not yet reached distant organs. The goal is to see if this approach is safe and effective.
Cleveland, OhioAges 18 years+ - NCT06506643RecruitingPhase 1/Phase 2
Study of KLS-1 for solid tumors and CLL
This trial tests a new drug called KLS-1 for people with solid tumors (like melanoma, pancreatic, or prostate cancer) or chronic lymphocytic leukemia (CLL) that is no longer responding to standard treatments. The goal is to see if KLS-1 is safe and can shrink tumors or slow the cancer.
KropyvnytskyiAges 18 years+ - NCT06385925RecruitingPhase 1/Phase 2
Study of TSN1611 for cancers with KRAS G12D mutation
This trial tests a new drug called TSN1611 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or stop them from growing.
Houston, TexasAges 18–75 - NCT04864054RecruitingPhase 1/Phase 2
Study T-cell therapy for advanced liver cancer
This trial tests a custom immune-cell treatment made to target a marker (GPC3) found on some liver cancers. It’s for adults with advanced HCC whose cancer has worsened after standard treatment or who couldn’t tolerate it.
Duarte, CaliforniaAges 18 years+ - NCT04749108RecruitingPhase 2/Phase 3
Tailored treatment for locally advanced rectal cancer after FOLFIRINOX
This trial studies a more customized treatment plan for people with locally advanced rectal (bowel) cancer after they receive FOLFIRINOX chemotherapy. It aims to reduce tumor spread risk and improve outcomes by tailoring the next steps based on scan details and your health status.
Marseille, Bouches Du RhôneAges 18 years+ - NCT04634357RecruitingPhase 1/Phase 2
Testing donor-like immune T cells for children with liver cancer
This Phase 1/2 trial tests an immune-cell treatment (ET140203 T cells) in children and teens with certain liver cancers that have come back or did not respond to standard treatment. It aims to see whether these T cells can shrink tumors and is mainly focused on safety and early effectiveness.
Los Angeles, CaliforniaAges 1–21 - NCT03114462RecruitingPhase 1
Study of focused radiation for laryngeal cancer
This Phase 1 study tests a precise type of radiation treatment for people with certain stages of laryngeal (voice box) squamous cell cancer. The goal is to see how safe the treatment is and how well it may work in shrinking or controlling the cancer while aiming to preserve the larynx.
Houston, TexasAges 18 years+ - NCT05733000RecruitingPhase 2
CPI-613 plus hydroxychloroquine with chemo for advanced solid tumors
This trial tests a drug called CPI-613 (devimistat) combined with hydroxychloroquine along with either 5-fluorouracil or gemcitabine chemo. It’s for people with advanced cancers that have stopped responding to standard treatments, aiming to shrink tumors and slow cancer growth.
Chicago, IllinoisAges 18 years+ - NCT07215988Recruiting
Studying insurance for skin cancer treatment
This study looks at how insurance covers immunotherapy given before surgery for certain skin cancers. It includes people with Merkel cell, mucosal melanoma, basal cell, or other rare skin cancers who are planning to have surgery.
Columbus, OhioAges 18 years+ - NCT07162038RecruitingPhase 1
CAR-T cells plus half-matched stem cell transplant for high-risk blood cancer
This trial tests giving special immune cells (CAR-T cells) that target a protein called CD19 on cancer cells, followed by a half-matched stem cell transplant, to treat high-risk blood cancers. The treatment aims to improve outcomes by using the CAR-T cells to reduce disease before the transplant.
Bethesda, MarylandAges 18–75 - NCT07059884Recruiting
Exercise program to help people with cancer stay active
This trial tests a distance-based exercise program designed to help people on chemotherapy maintain their physical function and prevent disability. It is for patients with certain cancers who are working full-time and can participate in moderate physical activity.
Dublin, CaliforniaAges 18 years+ - NCT06771739Recruiting
Paying patients with early-stage cancer extra money
This trial is testing whether giving patients with early-stage cancer extra money to pay for non-medical needs helps them. If you are getting treatment at PeaceHealth and have some financial worries, you may be able to join.
Bellingham, WashingtonAges 18 years+ - NCT06587490RecruitingPhase 3
Radiation therapy for limited metastatic cancers
This trial tests whether adding focused, high-dose radiation (SABR) to standard drug therapy can better control cancer that has spread to a few spots in the body. It is for people starting or resuming cancer medicines for newly found or growing metastases.
La Jolla, CaliforniaAges 18 years+ - NCT05830058RecruitingPhase 2
PET-guided focused radiation for limited worsening lung, melanoma, kidney cancer
This Phase 2 study tests whether using a PET scan to guide focused radiation (SBRT) can control a small number of cancer spots that are starting to grow despite prior treatment. It may help patients avoid wider radiation by targeting only the limited progressing areas.
Duarte, CaliforniaAges 18 years+ - NCT05327023RecruitingPhase 1/Phase 2
Donor immune cells after stem cell transplant for high-risk blood cancer
This trial uses donor immune cells (lymphocytes) after a stem cell transplant to help fight any remaining cancer in people with high-risk blood cancers. It aims to lower the chance of the cancer coming back.
Bethesda, MarylandAges 12–120 - NCT04959175RecruitingPhase 1/Phase 2
Lower-dose transplant drug for older or frail patients with blood cancer
This study tests whether a lower dose of a drug used after bone marrow transplant can reduce side effects while still preventing graft-versus-host disease (a condition where donor cells attack the patient's body). It is for older patients or those who are not healthy enough for a standard, stronger conditioning regimen.
Bethesda, MarylandAges 12–85
Hear when a new Metastatic Malignant Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic malignant neoplasm?
- Yes. Clin2 currently lists 247 recruiting metastatic malignant neoplasm studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic malignant neoplasm trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic malignant neoplasm trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Malignant Solid Neoplasm
- Metastatic Malignant Neoplasm in the Brain
- Metastatic Malignant Neoplasm in the Liver
- Metastatic Malignant Neoplasm in the Lung
- Metastatic Malignant Neoplasm in the Peritoneum
- Metastatic Malignant Neoplasm in the Bone
- Metastatic Malignant Neoplasm in the Leptomeninges
- Malignant Solid Neoplasm
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.